Long-term outcome of individuals with pure red cell aplasia and antierythropoietin antibodies in patients treated with recombinant epoetin: a follow-up report from the Research on Adverse Drug Events and Reports (RADAR) Project

Since its introduction in 1988, recombinant human erythropoietin (epoetin) has been standard treatment for patients with anemia due to chronic kidney disease. From 1998 to 2004, nearly 200 epoetin-treated persons with chronic kidney disease developed antibodies to epoetin, resulting in pure red cell...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: Bennett, Charles L., Cournoyer, Denis, Carson, Kenneth R., Rossert, Jerome, Luminari, Stefano, Evens, Andrew M., Locatelli, Francesco, Belknap, Steven M., McKoy, June M., Lyons, E. Alison, Kim, Benjamin, Sharma, Rishi, Costello, Stacey, Toffelmire, Edwin B., Wells, George A., Messner, Hans A., Yarnold, Paul R., Trifilio, Steven M., Raisch, Dennis W., Kuzel, Timothy M., Nissenson, Allen, Lim, Lay-Cheng, Tallman, Martin S., Casadevall, Nicole
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: The American Society of Hematology 2005
Aiheet:
Clinical Trials and Observations
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC1895064/
https://ncbi.nlm.nih.gov/pubmed/16099877
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2005-02-0508
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia